Kaplan–Meier survival analysis indicated that glioma patients with high NUP37 expression experienced significantly lower overall survival, disease-specific survival, and progression-free survival than those with low NUP37 expression (Fig. 1B). This evidence concerns the gene NUP37 and central nervous system cancer.